Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07081532 dose-ranging study in adults with type 2 diabetes or obesity
jRCT2031220457Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of lotiglipron in type 2 diabetes mellitus (T2DM) and obesity (5 arms), sponsored by Pfizer. Started Nov 2022; status: completed.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on jRCT2031220457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220457.